*By Christian Smith*
After an overdose earlier this week, Demi Lovato's life was reportedly saved by Narcan, a nasal administrator of naloxone that counteracts the effects of opioids. When administered quicklyーthrough either nasal mist or injectionーnaloxone can temporarily halt an overdose, allowing EMTs enough time to respond. The medication is available without a prescription in 49 states, and the generic version costs about $20 per dose.
But all merits aside, is the drug's accessibility enabling addicts to push their limits?
Dr. Roger Crystal, the lead inventor of Narcan and CEO of Opiant Pharmaceuticals, says there's little evidence to support that concern.
"Addiction like any kind of chronic disease is something you can control using better medication, but ultimately you can't cure," Crystal told Cheddar. "To think about an opioid addict behaving rationally and saying, 'well because I have access to Narcan I'll shoot more heroin, inject more heroin' there's no proof for that whatsoever."
Naloxone is considered some of the best ammunition on the front lines of America's growing opioid epidemic. A reported 2 million Americans have an addition to opioidsーand the number isn't going down. U.S. Surgeon General Jerome Adams [issued an advisory](https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html) in April urging anyoneーand their close family and friendsーwho uses painkillers, heroin, fentanyl, or other opioids to carry naloxone in case of an emergency.
Crystal isn't stopping at Narcan: he told Cheddar he's also developing a heroin vaccine, suggesting the inventor has lofty ambitions for the future of overdose prevention.
Although Crystal may be aware of lingering ethical concerns, he doesn't think they dwarf his mission. After all, Lovato has him to thank.
"Putting it in the hands of everyone and anyone is critical," Crystal said.
For more on this story, [click here](https://cheddar.com/videos/how-one-pharmaceutical-company-is-fighting-the-opioid-epidemic).
These are the headlines you Need 2 Know.
Relief for migraine suffers may, at long last, be imminent. With the FDA approving Eli Lilly's Emgality drug, Christi Shaw, president of Lilly Bio-Medicines, expounded on the drug's potential efficacy. The company has said it will offer the treatment to chronic migraine suffers with commercial insurance for free for a year.
These are the headlines you Need 2 Know.
These are the headlines you Need 2 Know.
Facebook announced its newest VR headset that will ship next year. "Oculus Quest" offers users the same virtual experience, but now users are able to move more freely while wearing the headset. Andrew Bosworth, VP of VR/AR at Facebook, said this is the next step in better connecting people around the world.
North Carolina is facing a new crisis a week after Hurricane Florence made landfall. Not only have millions of farm animals drowned in the initial floods. Now, flooded waste lagoons are contaminating the drinking water, explained Zoë Schlanger, environment reporter for Quartz.
Tilray, the Canadian cannabis company swiftly becoming one of the most talked-about stocks of the year, was up as much as 50 percent on Wednesday morning, leading a continued bull run in pot stocks and putting its market cap above established companies like Macy's and Viacom.
Elon Musk and SpaceX announced the company's first private passenger, Japanese billionaire Yusaku Maezawa. Shannon Stirone, freelance science journalist, said that this is the first step to Musk's ultimate goal ー transporting people to Mars.
Insurers should expect losses in the tens of billions of dollars due to Hurricane Florence's rain, which will linger for days because of the system's slow movement, said Mark Watson, CEO of Argo Group.
Natural disasters, hurricanes especially, were once opportunities for administrations to flex their leadership and empathy muscles. When they failed (see: Bush, Katrina), the results were politically devastating. When they succeeded (see: Christie, Sandy), they launched runs for office. Those days appear to be over.
